Multiple MyelomaPhase 2TRI ProNCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 2 study testing Ramantamig and Tocilizumab in people with Multiple Myeloma, run by Janssen Research & Development, LLC at 38 sites in 9 countries.
Trial summary
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Ramantamig and Tocilizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 230 participants
- Where
- 38 sitesin 9 countries
- Study dates
- 30 Jun 2026to 8 Nov 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Who cannot join
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Trial locations and contacts
38 sites in 9 countries. Contact the study team or a site near you to ask about taking part.
38 sites in 9 countries
Greece6 sites, 6 recruiting
- Recruiting
Uni General Hospital of Alexandroupolis
Alexandroupoli, 681 00
- Recruiting
251 Air Force General Hospital
Athens, 115 25
- Recruiting
Alexandra General Hospital of Athens
Athens, 11528
- Recruiting
General University Hospital of Patras
Rio, 265 04
- Recruiting
Theageneio Cancer Hospital
Thessaloniki, 546 39
- Recruiting
Hippokration Hospital
Thessaloniki, 54642
United States5 sites, 5 recruiting
- Recruiting
Beverly Hills Cancer Center (BHCC)
Beverly Hills, California, 90211
- Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, 80218
- Recruiting
City of Hope Phoenix
Goodyear, Arizona, 85338
- Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, 92618
- Recruiting
Washington University School Of Medicine
St Louis, Missouri, 63110
Malaysia5 sites, 5 recruiting
- Recruiting
Hospital Ampang
Ampang, 68000
- Recruiting
Hospital Pulau Pinang
George Town, 10450
- Recruiting
Hospital Sultanah Aminah
Johor Bharu, 80100
- Recruiting
Hospital Queen Elizabeth
Kota Kinabalu, 88586
- Recruiting
Sarawak General Hospital
Kuching, 93586
Sweden5 sites, 5 recruiting
- Recruiting
Falu Lasarett Medicinkliniken Falun
Falun, 791 82
- Recruiting
Sahlgrenska Universitetssjukhuset
Gothenburg, 413 45
- Recruiting
Skanes universitetssjukhus
Lund, 221 85
- Recruiting
Karolinska University Hospital Huddinge
Stockholm, 141 86
- Recruiting
Akademiska Sjukhuset
Uppsala, 752 37
Argentina4 sites, 4 recruiting
- Recruiting
Hospital Aleman
Buenos Aires, C1118
- Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, C1199ABB
- Recruiting
Instituto Alexander Fleming
Buenos Aires, C1426ANZ
- Recruiting
Hospital Privado Centro Medico de Cordoba
Córdoba, X5016KEH
France4 sites, 4 recruiting
- Recruiting
Centre Hospitalier Victor Dupouy
Argenteuil, 95107
- Recruiting
Centre Hospitalier de la Cote Basque
Bayonne, 64100
- Recruiting
Centre de Cancerologie de la Sarthe
Le Mans, 72100
- Recruiting
CHU Nantes - Hotel Dieu
Nantes, 44000
Portugal4 sites, 4 recruiting
- Recruiting
Uls Braga - Hosp. Braga
Braga, 4710 243
- Recruiting
Hosp. Cuf Descobertas
Lisbon, 1998 018
- Recruiting
Uls Santo Antonio - Hosp. Santo Antonio
Porto, 4050 342
- Recruiting
Uls Sao Joao - Hosp. Sao Joao
Porto, 4200 319
Spain3 sites, 3 recruiting
- Recruiting
Hosp. Univ. La Paz
Madrid, 28046
- Recruiting
Hosp. de Navarra
Pamplona, 31008
- Recruiting
Hosp. Univ. Dr. Peset
Valencia, 46017
Australia2 sites, 2 recruiting
- Recruiting
Concord Repatriation General Hospital
Concord, 2139
- Recruiting
Wollongong Hospital
Wollongong, 2500
About this study
Official title: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
- Conditions
- Multiple Myeloma
- Being tested
- Ramantamig, Tocilizumab, Placebo
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RamantamigDrug
Also called JNJ-79635322
Ramantamig will be administered as subcutaneous (SC) injection.
TocilizumabDrug
Tocilizumab will be administered as intravenous (IV) injection.
PlaceboDrug
Placebo (saline) will be administered as IV injection.
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Tocilizumab + Ramantamig | Experimental | Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). Receives: Drug: Ramantamig; Drug: Tocilizumab |
| Arm B: Placebo + Ramantamig | Placebo comparator | Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). Receives: Drug: Ramantamig; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.
Measured: By the end of Day 28 from first ramantamig dose
Secondary outcomes (14)
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported.
Measured: By the end of Day 28 from first ramantamig dose
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported.
Measured: Up to 38 months
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported.
Measured: Up to 38 months
Percentage of Participants with Re-occurrence of CRS for All Grades
Percentage of participants with re-occurrence of CRS for all Grades will be reported.
Measured: Up to 38 months
Overall Response
Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria.
Measured: Up to 38 months
Complete Response (CR) or Better
CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.
Measured: Up to 38 months
Very Good Partial Response (VGPR) or Better
VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.
Measured: Up to Month 38
Duration of Response (DoR)
DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first.
Measured: Up to 38 months
Time to Response (TTR)
TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response.
Measured: Up to 38 months
Progression-Free Survival (PFS)
PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.
Measured: Up to Month 38
Time to Subsequent Antimyeloma Therapy
Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.
Measured: Up to Month 38
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.
Measured: Up to 38 months
Percentage of Participants with Abnormalities in Laboratory Parameters
Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.
Measured: Up to 38 months
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported.
Measured: Up to 38 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start30 Jun 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion8 Nov 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 230 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07589634
- Sponsor's protocol ID
- 79635322MMY2002
- Other IDs
- 2025-524793-42, 2025
- Acronym
- TRI Pro
- Status last verified
- Sep 2026
- First submitted
- 11 May 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- ClinicalTrials.gov ID
- NCT07589634
- Acronym / sponsor ID
- TRI Pro / 79635322MMY2002
- Conditions
- Multiple Myeloma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 30 Jun 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 8 Nov 2030 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: Tocilizumab + Ramantamig | Experimental | Drug: Ramantamig, Drug: TocilizumabParticipants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
| Arm B: Placebo + Ramantamig | Placebo comparator | Drug: Ramantamig, Drug: PlaceboParticipants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Key exclusion criteria (5 listed)
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RamantamigAlso: JNJ-79635322Ramantamig will be administered as subcutaneous (SC) injection. | Drug | Arm A: Tocilizumab + Ramantamig, Arm B: Placebo + Ramantamig |
| TocilizumabTocilizumab will be administered as intravenous (IV) injection. | Drug | Arm A: Tocilizumab + Ramantamig |
| PlaceboPlacebo (saline) will be administered as IV injection. | Drug | Arm B: Placebo + Ramantamig |
Primary outcome
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Time frame: By the end of Day 28 from first ramantamig dose
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.
14 secondary outcomes
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Time frame: By the end of Day 28 from first ramantamig dose
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Time frame: Up to 38 months
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Time frame: Up to 38 months
Percentage of Participants with Re-occurrence of CRS for All Grades
Time frame: Up to 38 months
Overall Response
Time frame: Up to 38 months
Complete Response (CR) or Better
Time frame: Up to 38 months
Very Good Partial Response (VGPR) or Better
Time frame: Up to Month 38
Duration of Response (DoR)
Time frame: Up to 38 months
Time to Response (TTR)
Time frame: Up to 38 months
Progression-Free Survival (PFS)
Time frame: Up to Month 38
Time to Subsequent Antimyeloma Therapy
Time frame: Up to Month 38
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Time frame: Up to 38 months
Percentage of Participants with Abnormalities in Laboratory Parameters
Time frame: Up to 38 months
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Time frame: Up to 38 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: Yes. The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Related trials for Multiple Myeloma
RecruitingObservational study
Family Study of Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
RecruitingPhase 1
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Myeloma, Multiple Myeloma
Not yet recruiting
A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting
Myeloma
RecruitingObservational study
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Graft-versus-leukemia, Graft vs Host Disease
Not yet recruiting
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
Cardiotoxicity, Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
38 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ramantamig and Tocilizumab in people with Multiple Myeloma, run by Janssen Research & Development, LLC at 38 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in Greece, United States, Malaysia, Sweden, Argentina and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Contact (844-434-4210, Participate-In-This-Study1@its.jnj.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS) (time frame: By the end of Day 28 from first ramantamig dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.